Procera AVH is a dietary supplement, but its current label does not support a claim that it treats memory loss. Its three-ingredient blend has limited clinical evidence and raises important dosing and safety questions. One short trial found improvement in a single memory measure among healthy adults, not people with dementia or Alzheimer's disease. Anyone experiencing memory changes should seek an evaluation rather than rely on this supplement.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What is in Procera AVH?
- What did the clinical study find?
- What does that evidence mean for memory loss?
- Why do the earlier advertising claims matter?
- Safety questions and practical next steps
What is in Procera AVH?
The current Procera AVH label lists a 1,515-mg proprietary blend containing acetyl-L-carnitine hydrochloride, vinpocetine, and huperzine A. A proprietary blend states the combined amount but does not reveal how much of each ingredient a serving contains.
Procera Health markets the product for "brain health and cognitive function." It also states that the supplement is not intended to diagnose, treat, cure, or prevent disease, according to the current Procera AVH product information. That distinction matters. General support for cognitive function is not the same as evidence that a product treats memory loss, dementia, or Alzheimer's disease.
What did the clinical study find?
A 2019 randomized, double-blind, placebo-controlled study enrolled 90 healthy adults ages 22 to 66. Participants received either a placebo or three avh capsules daily for 28 days. The study formulation supplied 1,500 mg of acetyl-L-carnitine, 15 mg of vinpocetine, and 150 micrograms of huperzine A per day.
Analyzable cognitive data were available for 77 participants, according to the published AVH trial. AVH performed better than placebo on a composite measure called "Quality of Memory," with a reported p-value of 0.0294. It did not show a between-group benefit for continuity or speed of memory.
What does that evidence mean for memory loss?
The result is a limited signal, not proof that Procera AVH treats memory loss. Only one composite memory score favored AVH, while two other memory measures did not. More importantly, the trial studied healthy adults.
It excluded people with dementia or Alzheimer's disease, as well as people taking anticoagulants or cognition-affecting drugs and people with several chronic conditions. Those exclusions prevent the study from establishing effectiveness or safety for many readers most concerned about memory loss. The current label's undisclosed ingredient amounts also make it impossible to confirm from the label whether today's product matches the doses tested in 2019.
Why do the earlier advertising claims matter?
In 2015, the Federal Trade Commission challenged claims that Procera AVH was clinically proven to reverse age-related mental decline or memory loss. The marketers agreed to pay $1.4 million to settle the deceptive-advertising charges, and the FTC said those claims lacked adequate substantiation in its settlement announcement.
A stipulated federal order permanently barred KeyView from making covered memory-improvement or cognitive-decline claims without adequate randomized, double-blind, placebo-controlled human testing and supporting records. The later 2019 trial does not establish treatment effectiveness in people who already have memory loss.
Safety questions and practical next steps
Vinpocetine presents a clear concern for pregnancy. The FDA advises pregnant women and women who could become pregnant not to take it because reviewed data associate vinpocetine with miscarriage or fetal harm.
The agency also says it has not evaluated vinpocetine's effectiveness for memory or focus on its vinpocetine safety page. Before considering Procera AVH: NCCIH says direct evidence that supplements prevent Alzheimer's disease or other dementias is lacking. It also warns that memory loss can result from treatable conditions or medication effects, making timely evaluation the most useful next action.
- Show the label to a health professional, especially if you take anticoagulants or medicines that affect cognition.
- Do not use the 2019 trial as proof of safety if you have dementia, Alzheimer's disease, or an excluded chronic condition.
- Avoid vinpocetine if you are pregnant or could become pregnant, following FDA advice.
- Arrange an evaluation for new or worsening memory problems instead of delaying care.
